AbbVie Inc.
$522.35B- Market cap
- $462.58B
- Debt
- +$65.00B
- Cash
- −$5.23B
Capital structure 88% equity / 12% debt · EV / Revenue 8.54x · EV proxy / EBITDA proxy 22.50x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $462.58B · View financials
Snapshot Sep 14, 2026, 4:00 PM ET
FY 2025 ·
Decision snapshot: ABBV stock price vs XRX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at XRX's multiple
Needs XRX P/E.
Implied fair value · at ABBV's multiple
Needs Annual EPS is negative.
Snapshot Sep 14, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Multiple premium
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 88% equity / 12% debt · EV / Revenue 8.54x · EV proxy / EBITDA proxy 22.50x
Capital structure 10% equity / 90% debt · EV / Revenue 0.56x
ABBV carries the larger enterprise value at $522.35B against $3.94B; XRX trades on the lower EV / Revenue multiple (0.56x vs 8.54x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AbbVie Inc. · implied price per share
Bear
$87.89
Base
$110.94
Bull
$142.98
XEROX HOLDINGS CORPORATION · implied price per share
Bear
-$1.76
Base
$1.34
Bull
$6.85
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
ABBV vs PFE
Johnson & Johnson
ABBV vs JNJ
Merck & Co., Inc.
ABBV vs MRK
Eli Lilly and Company
ABBV vs LLY
Amgen Inc.
ABBV vs AMGN
Gilead Sciences, Inc.
ABBV vs GILD
HP INC
ABBV vs HPQ
STRATASYS LTD.
ABBV vs SSYS
3D SYSTEMS CORP
ABBV vs DDD
EASTMAN KODAK CO
ABBV vs KODK
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.